Loading clinical trials...
Loading clinical trials...
A Multi-centre, Open-label Trial Evaluating Efficacy, Safety and Pharmacokinetics of Turoctocog Alfa Pegol (N8-GP) When Used for Treatment and Prophylaxis of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Conditions
Interventions
turoctocog alfa pegol (N8-GP)
Locations
11
China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital-Hematology
Fuzhou, Fujian, China
Nanfang Hospital, Southern Medical University-Haematology
Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University-Hematology
Guiyang, Guizhou, China
Xiangya Hospital Central-South University
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
September 27, 2021
Primary Completion Date
December 28, 2022
Completion Date
December 28, 2022
Last Updated
January 6, 2026
NCT06716814
NCT06352216
NCT06831734
NCT06285071
NCT06752850
NCT02137850
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions